(CPHI) China Pharma Holdings - Ratings and Ratios
Exchange: NYSE MKT • Country: China • Currency: USD • Type: Common Stock • ISIN: US16941T1043
CPHI: Injectables, Tablets, Capsules, Sanitizers
China Pharma Holdings, Inc. (NYSE MKT: CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and distributing generic and branded pharmaceutical, biochemical, and healthcare products in the Peoples Republic of China. The company specializes in producing injectables, tablets, capsules, and oral solutions targeting cardiovascular, cerebrovascular, and neurological conditions, among others. Its product portfolio includes treatments for memory decline, cerebral thrombosis, hypertension, and infectious diseases, as well as supplements and personal protective equipment (PPE) such as sanitizers and masks.
The company operates through a network of distributors, sales offices, and representatives, ensuring broad access to its products across China. Its offerings include prescription drugs, over-the-counter medications, and health supplements, addressing a wide range of medical needs. With a market capitalization of $3.69 million and a price-to-book ratio of 0.68, the stock is currently trading at $0.23, with a 20-day average volume of 590,214 shares. The 20-day, 50-day, and 200-day moving averages are aligned at $0.22 and $0.23, respectively, indicating stable price action. The average true range (ATR) of $0.03 reflects low volatility.
3-Month Forecast: Based on
Additional Sources for CPHI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CPHI Stock Overview
Market Cap in USD | 4m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2002-04-17 |
CPHI Stock Ratings
Growth 5y | -91.8% |
Fundamental | -32.5% |
Dividend | 0.0% |
Rel. Strength Industry | -32.6 |
Analysts | - |
Fair Price Momentum | 0.14 USD |
Fair Price DCF | - |
CPHI Dividends
No Dividends PaidCPHI Growth Ratios
Growth Correlation 3m | 47.7% |
Growth Correlation 12m | -68.9% |
Growth Correlation 5y | -92.1% |
CAGR 5y | -60.77% |
CAGR/Max DD 5y | -0.61 |
Sharpe Ratio 12m | -0.12 |
Alpha | -42.70 |
Beta | 1.00 |
Volatility | 174.16% |
Current Volume | 443.6k |
Average Volume 20d | 653k |
As of March 15, 2025, the stock is trading at USD 0.24 with a total of 443,649 shares traded.
Over the past week, the price has changed by +6.36%, over one month by +13.10%, over three months by +47.17% and over the past year by -32.01%.
Probably not. Based on ValueRay Fundamental Analyses, China Pharma Holdings (NYSE MKT:CPHI) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -32.48 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CPHI as of March 2025 is 0.14. This means that CPHI is currently overvalued and has a potential downside of -41.67%.
China Pharma Holdings has no consensus analysts rating.
According to ValueRays Forecast Model, CPHI China Pharma Holdings will be worth about 0.2 in March 2026. The stock is currently trading at 0.24. This means that the stock has a potential downside of -37.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 1150% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.2 | -37.5% |